Stephens Inc. AR decreased its position in Allergan plc (NYSE:AGN) by 12.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,606 shares of the company’s stock after selling 3,602 shares during the quarter. Stephens Inc. AR’s holdings in Allergan were worth $4,025,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Cable Hill Partners LLC raised its position in Allergan by 255.2% in the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after purchasing an additional 370 shares during the period. Rockefeller Financial Services Inc. raised its position in Allergan by 283.7% in the third quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock valued at $111,000 after purchasing an additional 400 shares during the period. Phocas Financial Corp. purchased a new stake in Allergan in the second quarter valued at approximately $150,000. BB&T Investment Services Inc. raised its position in Allergan by 1,308.2% in the third quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock valued at $139,000 after purchasing an additional 641 shares during the period. Finally, WFG Advisors LP raised its position in Allergan by 20.9% in the second quarter. WFG Advisors LP now owns 793 shares of the company’s stock valued at $193,000 after purchasing an additional 137 shares during the period. 80.23% of the stock is currently owned by institutional investors.

In other news, insider William Meury sold 11,807 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $173.89, for a total transaction of $2,053,119.23. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Chris W. Bodine bought 3,030 shares of the firm’s stock in a transaction dated Thursday, December 7th. The shares were acquired at an average price of $164.77 per share, with a total value of $499,253.10. The disclosure for this purchase can be found here. Insiders have bought 17,630 shares of company stock valued at $2,890,057 in the last quarter. Insiders own 0.36% of the company’s stock.

AGN has been the topic of a number of research analyst reports. Cowen reissued a “buy” rating on shares of Allergan in a research report on Thursday, October 12th. Cantor Fitzgerald set a $231.00 target price on Allergan and gave the company a “hold” rating in a research report on Thursday, October 12th. Piper Jaffray Companies set a $227.00 target price on Allergan and gave the company a “hold” rating in a research report on Friday, October 13th. Wells Fargo & Co set a $276.00 price objective on Allergan and gave the stock a “buy” rating in a research report on Friday, October 13th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $275.00 price objective on shares of Allergan in a research report on Monday, October 16th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the stock. Allergan currently has an average rating of “Buy” and a consensus price target of $227.23.

Allergan plc (AGN) opened at $170.39 on Thursday. The company has a quick ratio of 1.08, a current ratio of 2.04 and a debt-to-equity ratio of 0.41. Allergan plc has a 12 month low of $160.07 and a 12 month high of $256.80. The stock has a market cap of $55,983.71, a price-to-earnings ratio of -12.70, a price-to-earnings-growth ratio of 1.24 and a beta of 1.19.

Allergan (NYSE:AGN) last released its quarterly earnings data on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.28%. The company had revenue of $4.33 billion during the quarter, compared to the consensus estimate of $4.28 billion. During the same quarter in the prior year, the firm posted $3.90 earnings per share. Allergan’s revenue for the quarter was up 12.0% on a year-over-year basis. equities research analysts forecast that Allergan plc will post 15.41 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.dailypolitical.com/2018/02/08/stephens-inc-ar-has-4-03-million-stake-in-allergan-plc-agn.html.

About Allergan

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.